Eli Lilly and Company / Avid Radiopharmaceuticals, Inc.
2011 · Acquisition/Merger · $800M · Complete
Announcement Sentiment
86
Strongly positive
Lilly completed the acquisition of Avid Radiopharmaceuticals, gaining florbetapir F 18 (later branded Amyvid), a PET imaging agent designed to detect beta-amyloid plaques in living patients; deal included $300M upfront and up to $500M in development/regulatory milestones.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Assets Advanced
Assessment window: 10yr post-close.
Key facts
AnnouncedJan 11, 2011
ClosedJan 20, 2011
Deal value$800M
Deal typeAcquisition/Merger
Therapeutic areaAlzheimer's beta-amyloid PET imaging
IndicationsAlzheimer's beta-amyloid PET imaging
Key assetsflorbetapir F 18 (Amyvid)
MechanismF-18 PET imaging agent binding beta-amyloid plaque